NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Neuraxis, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$7.85+0.15 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $95.14M
- P/E (TTM)
- –
- Dividend yield
- –
Neuraxis, INC revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q4 23 | TTM Q4 22 | % of revenue | YoY |
|---|---|---|---|---|
| All other States [Member] | $726.48K | $699.13K | 32.8% | +3.9% |
| Canada | $601.24K | $408.65K | 27.1% | +47.1% |
| OH | $407.63K | $500.26K | 18.4% | -18.5% |
| WI | $292.60K | $670.25K | 13.2% | -56.3% |
| FL | $186.84K | $231.48K | 8.4% | -19.3% |
| Macao SAR China | – | $174.98K | – | – |
From the segment and revenue-disaggregation notes of Neuraxis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.